唐海东 - 清华大学

个人简介

唐海东博士，本科毕业于南京大学，随后于中科院生物物理所获得博士学位。先后在美国芝加哥大学、德克萨斯大学西南医学中心从事博士后工作，主要研究方向为肿瘤免疫学与免疫治疗。2018年加入清华大学药学院开展独立研究。荣誉和奖项 2019年Bayer Investigator Award 2014年Irvington Postdoctoral Fellowship, Cancer Research Institute (New York) 2012年北京生命科学研究院和赛诺菲巴斯德生物医学杰出研究生奖

研究领域

癌症的治疗是我国乃至全球经济社会发展所面临的严峻挑战。相比于传统疗法，近年来兴起的免疫治疗采用了新的策略，并取得了突破性的进展。然而，目前仅有小部分肿瘤患者能够从免疫治疗中获益，且肿瘤针对治疗产生的耐药时有发生。如何改进现有免疫疗法的效果，成为亟待解决的问题。本课题组综合运用小鼠动物模型、抗体工程技术、高通量筛选等方法与手段，聚焦研究肿瘤微环境中的免疫调节机制，以及它们在免疫治疗中的功能与应用。具体研究方向包括：1）筛选与鉴定肿瘤发生与转移过程中的驱动因子，并研发新的免疫治疗策略；2）研究肿瘤微环境中的免疫抑制与免疫激活调控机制，以及它们在免疫治疗中的作用；3）设计与研发新的可用于肿瘤免疫治疗的下一代抗体药物。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, Guo J, Peng H, Chen M, Fu Y-X, Tang H#. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020, 11: 4835. Zuo H, Yang D, Yang Q, Tang H, Fu Y-X, Wan Y. Differential regulation of breast cancer bone metastasis by PARP1 and PARP2. Nat Commun. 2020, 11: 1578. Tang H#, Liang Y#, Anders R, Taube J, Qiu X, Mulgaonkar A, Liu X, Harrington S, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Peng H, Dong H, Fu Y-X. PD-L1 on host cells is essential for tumor regression mediated by PD-L1 blockade. J Clin Invest. 2018, 128: 580-588. Tang H*, Qiu X, Timmerman C, Fu Y-X. Targeting tertiary lymphoid structures for tumor immunotherapy. Methods Mol Biol. 2018, 1845: 275-286. Tang H, Fu Y-X. Immune Evasion in Tumor’s Own Sweet Way. Cell Metab. 2018, 27: 945-946. Liang Y#, Tang H#*, Guo J#, Qiu X, Ren Z, Bian Y, Dong H, Peng H*, Fu Y-X*. Targeting type I interferon into tumor by anti-PD-L1 creates feedforward antitumor responses to overcome innate and adaptive resistance. Nat Commun. 2018, 9: 4586. Lu K, He C, Guo N, Chan C, Ni K, Lan G, Tang H, Pelizzari C, Fu Y-X, Spiotto M, Weichselbaum R, Lin W. Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy. Nat Biomed Eng. 2018, 2: 600-610. Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, Lu Z, Xie J, Churchill H, Xu Y, Zhou Z, Wu G, Yu C, John S, Hirayasu K, Nguyen N, Liu X, Huang F, Li L, Deng H, Tang H, Sadek AH, Zhang L, Huang T, Zou Y, Chen B, Zhu H, Arase H, Xia N, Jiang Y, Collins R, You MJ, Homsi J, Unni N, Lewis C, Chen GQ, Fu YX, Liao XC, An Z, Zheng J, Zhang N, Zhang CC. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018, 562: 605-609. Zhang Y, Kim T-J, Wroblewska J, Tesic V, Upadhyay V, Weichselbaum R, Tumornoy A, Tang H, Guo X, Tang H, Fu Y-X. Type 3 innate lymphoid cell-derived lymphotoxin prevents microbiota-dependent inflammation. Cell Mol Immunol. 2017, 14: 1-13. Tang H*, Zhu M, Qiao J, Fu Y-X*. Lymphotoxin signaling in tertiary lymphoid structures and immunotherapy. Cell Mol Immunol. 2017, 14: 809-818. Qiao J, Tang H, Fu Y-X. DNA sensing and immune responses in cancer therapy. Curr Opin Immunol. 2017, 45: 16-20. Wroblewska J, Zhang Y, Tang H, Guo X, Nagler C, Fu Y-X. Cutting Edge: Lymphotoxin Signaling Is Essential for Clearance of Salmonella from the Gut Lumen and Generation of Anti-Salmonella Protective Immunity. J Immunol. 2017, 198: 55-60. Tang H, Wang Y, Chlewicki L, Zhang Y, Guo J, Liang W, Wang J, Wang X, Fu Y-X. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016, 29 (3): 285-296. Tang H, Qiao J, Fu Y-X. Immunotherapy and tumor microenvironment. Cancer Lett. 2016, 370: 85-90. Okwor I, Xu G, Tang H, Liang Y, Fu Y-X, Uzonna J. Deficiency of CD40 reveals an important role for LIGHT in anti-Leishmania immunity. J Immunol. 2015, 195: 194-202. Li C, Yang Z, Du Y, Tang H, Chen J, Hu D, Fan Z. BCMab1, A monoclonal antibody against aberrantly glycosylated integrin a3b1, has potent antitumor activity of bladder cancer in vivo. Clin Cancer Res, 2014, 20: 4001-4013. Tang H, Li C, Wang L, Zhang H, Fan Z. Granzyme H of cytotoxic lymphocytes is required for clearance of the hepatitis B virus through cleavage of the hepatitis B virus X protein. J Immunol.2012, 188: 824-831. Yang Z, Tang H, Huang H, Deng H. RTA promoter demethylation and histone acetylation regulation of murine gamma-herpesvirus 68 reactivation. PLoS One. 2009, 4 (2): e4556.